|
|
| Phase | 1 |
| Enrolling | 18 participants |
| Therapy | Decitabine and Bexarotene |
| Category | |
|
The investigators are seeking to study the combination of decitabine and bexarotene. These
two agents have each shown efficacy in decreasing leukemic blast counts and restoring normal
hematopoiesis via different mechanisms of action and w...
Washington University School of Medicine - Started 16 days ago
|
| Phase | 1 |
| Enrolling | 18 participants |
| Therapy | Plerixafor, Mitoxantrone, Etoposide, Cytarabine |
| Category | |
|
In this phase I extension study, the investigators seek to test the safety of both higher
doses of plerixafor as well as intravenous dosing to maximize inhibition of the target,
CXCR4.
Washington University School of Medicine - Started 16 days ago
|
|
An open-label phase 1/2 study to assess safety and efficacy of once-weekly STA-9090 in
subjects with AML, ALL and blast-phase CML.
Synta Pharmaceuticals, Corp. - Started 7 months ago
|
|
leukemia. These T cells are removed from blood, modified in a laboratory, and then put back... that allows them to recognize and kill the leukemia cells. This gene will be put
in the T cells... the leukemia cells and possibly kill them. The doctors have
found that T cells modified in this way can...
Memorial Sloan-Kettering Cancer Center - Started 2 months ago
|
|
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of
lenalidomide that can be given in combination with azacitidine to patients with
Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).
The goal of Phase 2 of this study is to learn...
M.D. Anderson Cancer Center - Started 3 months ago
|
|
|
